Retaspimycin

Retaspimycin is a potent inhibitor of Hsp90, with EC50s of 119 nM for both Hsp90 and Grp9.

Product Specifications

CAS Number

[857402-23-4]

UNSPSC

12352005

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/retaspimycin.html

Solubility

10 mM in DMSO

Smiles

OC1=C(C[C@H](C[C@@H]([C@@H]2O)OC)C)C(NCC=C)=C(C=C1NC(/C(C)=C/C=C/[C@@H]([C@H](/C(C)=C/[C@@H]2C)OC(N)=O)OC)=O)O

Molecular Formula

C31H45N3O8

Molecular Weight

587.70

References & Citations

[1]Sydor JR, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006 Nov 14;103 (46) :17408-13. Epub 2006 Nov 7.|[2]Floris G, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther. 2011 Oct;10 (10) :1897-908.|[3]Scaltriti M, et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther. 2011 May;10 (5) :817-24.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

Phase 3

Isoform

HSP90

Citation 01

Theranostics. 2019 Aug 12;9 (20) :5769-5783.|Transl Oncol. 2019 Apr 3;12 (6) :801-809.|FASEB J. 2023 Mar;37 (3) :e22832.|J Cell Biochem. 2025 Apr;126 (4) :e70031.